Bristol Myers Squibb (BMY) Other Non Operating Income (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Other Non Operating Income data on file, last reported at -$32.0 million in Q1 2026.

• Quarterly Other Non Operating Income rose 90.56% year-over-year to -$32.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$367.0 million (up 68.11% YoY) and the FY2025 annual result came in at -$674.0 million, up 24.52% from the prior year.
• Other Non Operating Income fell to -$32.0 million in Q1 2026 per BMY's latest filing, from $51.0 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $413.0 million in Q1 2023 and bottomed at -$649.0 million in Q1 2022.
• The 5-year median for Other Non Operating Income is -$32.0 million (2026), against an average of -$59.8 million.
• The widest annual swing landed in 2022, when Other Non Operating Income slumped 14300.0%; it then soared 163.64% in 2023.
• Tracing BMY's Other Non Operating Income over 5 years: stood at $217.0 million in 2022, then jumped by 70.97% to $371.0 million in 2023, then tumbled by 182.21% to -$305.0 million in 2024, then jumped by 116.72% to $51.0 million in 2025, then sank by 162.75% to -$32.0 million in 2026.
• Per Business Quant, the three latest BMY Other Non Operating Income figures stand at -$32.0 million (Q1 2026), $51.0 million (Q4 2025), and $108.0 million (Q3 2025).

Peer Comparison